not too sure, this was from the market update 3 weeks ago
Full year FY17 expected preliminary financial performance
(All numbers are preliminary, unaudited and subject to final sign-off by the Board)
Mayne Pharma Group Limited’s preliminary full year FY17 results1 are anticipated to be the
following:
• Total revenue of approximately A$581 million;
• Underlying EBITDA of between A$212 - A$216 million2
(excluding A$25m non-cash
charge); and
• Reported NPAT of between A$92 - A$95 million
the actual NPAT came lower than the confession $88.6M
still solid for the company but came in lower than the revised estimate
Ann: Preliminary Final Report, page-6
Add MYX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$4.88 |
Change
-0.010(0.20%) |
Mkt cap ! $415.1M | |||
| Open | High | Low | Value | Volume |
| $4.96 | $4.97 | $4.74 | $916.4K | 188.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 986 | $4.88 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $4.90 | 540 | 1 |
View Market Depth
| Last trade - 16.10pm 14/11/2024 (20 minute delay) ? |
| MYX (ASX) Chart |